Hairy Cell Leukemia Market

Hairy Cell Leukemia Market by Therapies (Chemotherapy and Targeted Therapy) and Regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2042
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 190
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global hairy cell leukemia market size is anticipated to expand at a robust CAGR during the forecast period, 2021-2028. The growth of the market is attributed to rising awareness about the hairy cell leukemia coupled with rising disposable income. Moreover, increasing diagnosis rate of hairy cell leukemia is driving the market growth.

Hairy Cell Leukemia Market key takeaways

Hairy cell leukemia is a rare type of blood cancer that is caused due to abnormal growth of B- cells. The outgrown B cells or B lymphocyte when examined under a microscope looks similar to hair extending from the surface area, which gives the cancer its name. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow.

Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. There are advanced diagnostic tests to detect the hairy cell leukemia. In one of the diagnostic tests, the blood profile indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose the cancer by physical examination. Most of the patients also require bone marrow biopsy for confirmation.

Market Trends, Drivers, Restraints, and Opportunities:

  • Increasing R&D activities for the development of advanced therapy is driving the growth of the market.
  • Ongoing technological developments is expected to augment the hairy cell leukemia market growth.
  • High cost for the treatment can act as a major restraint for the market growth.
  • Efficiency of the treatment available is yet to be discover, limiting the market growth.
  • State government bodies are implementing programs to increase the awareness about the cancer, which is stimulating the growth of the market.
  • The presence of reimbursement programs is speculated to propel the hairy cell leukemia market.

Scope of the Report

The report on the global hairy cell leukemia market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Hairy Cell Leukemia market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Therapies (Chemotherapy and Targeted Therapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Hoffmann-La Roche Ltd, Janssen Global Services LLC, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Amgen Inc., Hospira, Astex Therapeutics, Pfizer Inc, AstraZeneca plc, BioGenomics Limited, Incyte Corp, Merck & Co Inc, Genentech, bluebird bio, Beam Therapeutics, Mission Bio, Roivant Sciences Inc., Humanigen, Fate Therapeutics, Kronos Bio, Tasso, PTC Therapeutics, Quantgene, Syros Pharmaceuticals, Oncoternal, GlycoMimetics, Notable Labs, Nuprobe, CARsgen, and Twinstrand Biosciences Inc.

 

Hairy Cell Leukemia Market Segment Insights:

Chemotherapy segment to grow at a rapid pace

Based on therapies, the market is divided into chemotherapy and targeted therapy. The chemotherapy is anticipated to account for a key share and is anticipated to grow at a robust rate during the forecast period. Chemotherapy drugs, such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia. This factor is driving the segment growth. However, the targeted therapy segment is expected to grow at a healthy CAGR owing to ongoing R&D activities for the hairy cell leukemia treatment.

Hairy Cell Leukemia Market by therapies

North America to account a large market share

On the basis of regions, the market is segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America to account for a large market share owing to advancements in technologies, high incidence, and increasing geriatric population. Conversely, the market in Asia Pacific is expected to register a substantial growth rate in global hairy cell leukemia market during the forecast period.

Segments

Segments Covered in the Report
The global hairy cell leukemia market has been segmented on the basis of

Therapies

  • Chemotherapy
  • Targeted Therapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Hoffmann-La Roche Ltd
  • Janssen Global Services LLC
  • Dr. Reddy's Laboratories
  • Emcure Pharmaceuticals
  • Amgen Inc.
  • Hospira
  • Astex Therapeutics
  • Pfizer Inc
  • AstraZeneca plc
  • BioGenomics Limited
  • Incyte Corp
  • Merck & Co Inc
  • Genentech
  • bluebird bio
  • Beam Therapeutics
  • Mission Bio
  • Roivant Sciences Inc.
  • Humanigen
  • Fate Therapeutics
  • Kronos Bio
  • Tasso
  • PTC Therapeutics
  • Quantgene
  • Syros Pharmaceuticals
  • Oncoternal
  • GlycoMimetics
  • Notable Labs
  • Nuprobe
  • CARsgen
  • Twinstrand Biosciences Inc.

Competitive Landscape

The major players of the market are Hoffmann-La Roche Ltd, Janssen Global Services LLC, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Amgen Inc., Hospira, Astex Therapeutics, Pfizer Inc, AstraZeneca plc, BioGenomics Limited, Incyte Corp, Merck & Co Inc, Genentech, bluebird bio, Beam Therapeutics, Mission Bio, Roivant Sciences Inc., Humanigen, Fate Therapeutics, Kronos Bio, Tasso, PTC Therapeutics, Quantgene, Syros Pharmaceuticals, Oncoternal, GlycoMimetics, Notable Labs, Nuprobe, CARsgen, and Twinstrand Biosciences Inc.

Companies are focusing on innovation, partnerships, and acquisitions to expand their market share.

Hairy Cell Leukemia Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hairy Cell Leukemia Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hairy Cell Leukemia Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hairy Cell Leukemia Market - Supply Chain
  4.5. Global Hairy Cell Leukemia Market Forecast
     4.5.1. Hairy Cell Leukemia Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hairy Cell Leukemia Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hairy Cell Leukemia Market Absolute $ Opportunity
5. Global Hairy Cell Leukemia Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hairy Cell Leukemia Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hairy Cell Leukemia Demand Share Forecast, 2019-2026
6. North America Hairy Cell Leukemia Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hairy Cell Leukemia Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hairy Cell Leukemia Demand Share Forecast, 2019-2026
7. Latin America Hairy Cell Leukemia Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hairy Cell Leukemia Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hairy Cell Leukemia Demand Share Forecast, 2019-2026
8. Europe Hairy Cell Leukemia Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hairy Cell Leukemia Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hairy Cell Leukemia Demand Share Forecast, 2019-2026
9. Asia Pacific Hairy Cell Leukemia Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hairy Cell Leukemia Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hairy Cell Leukemia Demand Share Forecast, 2019-2026
10. Middle East & Africa Hairy Cell Leukemia Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hairy Cell Leukemia Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hairy Cell Leukemia Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hairy Cell Leukemia Market: Market Share Analysis
  11.2. Hairy Cell Leukemia Distributors and Customers
  11.3. Hairy Cell Leukemia Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Hoffmann-La Roche Ltd
     11.4.2. Janssen Global Services LLC
     11.4.3. Dr. Reddy's Laboratories
     11.4.4. Emcure Pharmaceuticals
     11.4.5. Amgen Inc.
     11.4.6. Hospira
     11.4.7. Astex Therapeutics

Segments Covered in the Report
The global hairy cell leukemia market has been segmented on the basis of

Therapies

  • Chemotherapy
  • Targeted Therapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Hoffmann-La Roche Ltd
  • Janssen Global Services LLC
  • Dr. Reddy's Laboratories
  • Emcure Pharmaceuticals
  • Amgen Inc.
  • Hospira
  • Astex Therapeutics
  • Pfizer Inc
  • AstraZeneca plc
  • BioGenomics Limited
  • Incyte Corp
  • Merck & Co Inc
  • Genentech
  • bluebird bio
  • Beam Therapeutics
  • Mission Bio
  • Roivant Sciences Inc.
  • Humanigen
  • Fate Therapeutics
  • Kronos Bio
  • Tasso
  • PTC Therapeutics
  • Quantgene
  • Syros Pharmaceuticals
  • Oncoternal
  • GlycoMimetics
  • Notable Labs
  • Nuprobe
  • CARsgen
  • Twinstrand Biosciences Inc.

The major players of the market are Hoffmann-La Roche Ltd, Janssen Global Services LLC, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Amgen Inc., Hospira, Astex Therapeutics, Pfizer Inc, AstraZeneca plc, BioGenomics Limited, Incyte Corp, Merck & Co Inc, Genentech, bluebird bio, Beam Therapeutics, Mission Bio, Roivant Sciences Inc., Humanigen, Fate Therapeutics, Kronos Bio, Tasso, PTC Therapeutics, Quantgene, Syros Pharmaceuticals, Oncoternal, GlycoMimetics, Notable Labs, Nuprobe, CARsgen, and Twinstrand Biosciences Inc.

Companies are focusing on innovation, partnerships, and acquisitions to expand their market share.

Hairy Cell Leukemia Market by key players

Buy Report